Insulet Corporation is essentially flat in after-hours trading at $215.13 following a 4.2% decline during today's regular session. The stock remains under pressure as investors digest a recent investor alert regarding a potential securities fraud class action lawsuit, which stems from the company's March 12 disclosure of a voluntary medical device correction for its Omnipod 5 insulin pods. While institutional interest remains present, evidenced by a significant stake increase from Diversified Trust Co. reported in the last 12 hours, the ongoing legal uncertainty and negative sentiment surrounding the device defect continue to weigh on the share price. There is no new company-specific news released after today's market close to explain the marginal 0.4% movement in after-hours trading.
Click any event to see why PODD moved that day
No significant catalyst events detected.